Status: Recruiting
A Clinical Study of SHR-4506 Injection in Patients With Malignant Tumors
The study is being conducted to evaluate the safety and tolerability of SHR-4506 Injection in patients with malignant tumors and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD).
Participants needed: 102
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.Updated: May 18, 2026Locations: 2
Eligibility criteria
Age ≥18 years, any gender. [+7]
Prior treatment with the same class of investigational drug. [+11]